stoxline Quote Chart Rank Option Currency Glossary
  
Standard BioTools Inc. (FLDM)
3.71  -0.28 (-7.02%)    04-06 00:00
Open: 4.05
High: 3.99
Volume: 522,109
  
Pre. Close: 3.99
Low: 3.66
Market Cap: 294(M)
Technical analysis
2022-11-18 4:20:37 PM
Short term     
Mid term     
Targets 6-month :  4.55 1-year :  4.73
Resists First :  3.9 Second :  4.05
Pivot price 3.71
Supports First :  3.66 Second :  3.04
MAs MA(5) :  3.71 MA(20) :  3.71
MA(100) :  3.71 MA(250) :  3.54
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  12.8 D(3) :  12.8
RSI RSI(14): 64.7
52-week High :  4.84 Low :  1.63
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ FLDM ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.06 - 4.08 4.08 - 4.1
Low: 3.61 - 3.63 3.63 - 3.65
Close: 3.67 - 3.71 3.71 - 3.74
Company Description

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Headline News

Wed, 04 Oct 2023
Why SomaLogic Stock Dived by 10% on Wednesday - The Motley Fool

Mon, 14 Feb 2022
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital ... - Yahoo Finance

Mon, 24 Jan 2022
Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and ... - GlobeNewswire

Sun, 09 Aug 2015
Fluidigm's (FLDM) CEO Gajus Worthington on Q2 2015 Results - Earnings Call Transcript - Seeking Alpha

Thu, 30 Oct 2014
Fluidigm Corporation's (FLDM) CEO Gajus Worthington on Q3 2014 Results -- Earnings Call Transcript - Seeking Alpha

Sun, 21 Apr 2024

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 77 (M)
Shares Float 53 (M)
Held by Insiders 1.9 (%)
Held by Institutions 99.9 (%)
Shares Short 5,630 (K)
Shares Short P.Month 5,500 (K)
Stock Financials
EPS -0.79
EPS Est Next Qtrly -0.35
EPS Est This Year -1.96
EPS Est Next Year -1.3
Book Value (p.s.) 1.23
Profit Margin -45.4 %
Operating Margin -51.7 %
Return on Assets (ttm) -14.1 %
Return on Equity (ttm) -50.8 %
Qtrly Rev. Growth -14.2 %
Gross Profit (p.s.) 0.4
Sales Per Share 1.69
EBITDA (p.s.) -0.83
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio -4.75
PEG Ratio 0.5
Price to Book value 3.01
Price to Sales 2.19
Price to Cash Flow -6.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android